Skip to main content
Top
Published in: BMC Public Health 1/2021

Open Access 01-12-2021 | Human Immunodeficiency Virus | Research

Unsuppressed viral load after intensive adherence counselling in rural eastern Uganda; a case of Kamuli district, Uganda

Authors: Geoffrey Ndikabona, John Bosco Alege, Nicholas Sebuliba Kirirabwa, Derrick Kimuli

Published in: BMC Public Health | Issue 1/2021

Login to get access

Abstract

Background

The East Central (EC) region of Uganda has the least viral suppression rate despite having a relatively low prevalence of human immunodeficiency virus (HIV). Although the viral suppression rate in Kamuli district is higher than that observed in some of the districts in the region, the district has one of the largest populations of people living with HIV (PLHIV). We sought to examine the factors associated with viral suppression after the provision of intensive adherence counselling (IAC) among PLHIV in the district.

Methods

We reviewed records of PLHIV and used them to construct a retrospective cohort of patients that started and completed IAC during January – December 2019 at three high volume HIV treatment facilities in Kamuli district. We also conducted key informant interviews of focal persons at the study sites. We summarized the data descriptively, tested differences in the outcome (viral suppression after IAC) using chi-square and t-tests, and established independently associated factors using log-binomial regression analysis with robust standard errors at 5% statistical significance level using STATA version 15.

Results

We reviewed 283 records of PLHIV. The mean age of the participants was 35.06 (SD 18.36) years. The majority of the participants were female (56.89%, 161/283). The viral suppression rate after IAC was 74.20% (210/283). The most frequent barriers to ART adherence reported were forgetfulness 166 (58.66%) and changes in the daily routine 130 (45.94). At multivariable analysis, participants that had a pre-IAC viral load that was greater than 2000 copies/ml [adjusted Prevalence Risk Ratio (aPRR)= 0.81 (0.70 - 0.93), p=0.002] and those that had a previous history of viral load un-suppression [aPRR= 0.79 (0.66 - 0.94), p=0.007] were less likely to achieve a suppressed viral load after IAC. ART drug shortages were rare, ART clinic working hours were convenient for clients and ART clinic staff received training in IAC.

Conclusion

Despite the consistency in drug availability, counselling training, flexible and frequent ART clinic days, the viral suppression rate after IAC did not meet recommended targets. A high viral load before IAC and a viral rebound were independently associated with having an unsuppressed viral load after IAC. IAC alone may not be enough to achieve viral suppression among PLHIV. To improve viral suppression rates after IAC, other complementary services should be paired with IAC.
Literature
1.
go back to reference Nasuuna E, et al. Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda. BMC Public Health. 2018;18:1048.CrossRef Nasuuna E, et al. Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda. BMC Public Health. 2018;18:1048.CrossRef
2.
go back to reference Marsh K, et al. Global, regional and country-level 90–90–90 estimates for 2018: assessing progress towards the 2020 target. AIDS. 2019;33:S213.CrossRef Marsh K, et al. Global, regional and country-level 90–90–90 estimates for 2018: assessing progress towards the 2020 target. AIDS. 2019;33:S213.CrossRef
4.
go back to reference Maina EK, et al. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya. Int. J. Infect. Dis. 2020;97:151–8. Maina EK, et al. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya. Int. J. Infect. Dis. 2020;97:151–8.
5.
go back to reference Diress G, Dagne S, Alemnew B, Adane S, Addisu A. Viral Load Suppression after Enhanced Adherence Counseling and Its Predictors among High Viral Load HIV Seropositive People in North Wollo Zone Public Hospitals, Northeast Ethiopia, 2019: Retrospective Cohort Study. AIDS Res. Treat. 2020;2020:e8909232. Diress G, Dagne S, Alemnew B, Adane S, Addisu A. Viral Load Suppression after Enhanced Adherence Counseling and Its Predictors among High Viral Load HIV Seropositive People in North Wollo Zone Public Hospitals, Northeast Ethiopia, 2019: Retrospective Cohort Study. AIDS Res. Treat. 2020;2020:e8909232.
6.
go back to reference Tanner Z, et al. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infect. Dis. 2016;16:590. Tanner Z, et al. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infect. Dis. 2016;16:590.
7.
go back to reference Korobchuk A, et al. People with high HIV viral load within risk networks: who are these people and who refers them best? J. Infect. Dev. Ctries. 2019;13:103S–10S. Korobchuk A, et al. People with high HIV viral load within risk networks: who are these people and who refers them best? J. Infect. Dev. Ctries. 2019;13:103S–10S.
8.
go back to reference Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397–404.CrossRef Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397–404.CrossRef
9.
go back to reference Coll O, et al. Vertical HIV-1 transmission correlates with a high maternal viral load at delivery. J. Acquir. Immune Defic. Syndr. Hum. Retrovirology Off. Publ. Int. Retrovirology Assoc. 1997;14:26–30. Coll O, et al. Vertical HIV-1 transmission correlates with a high maternal viral load at delivery. J. Acquir. Immune Defic. Syndr. Hum. Retrovirology Off. Publ. Int. Retrovirology Assoc. 1997;14:26–30.
10.
go back to reference Fox MP, et al. Delays in repeat HIV viral load testing for those with elevated viral loads: a national perspective from South Africa. J. Int. AIDS Soc. 2020;23:e25542. Fox MP, et al. Delays in repeat HIV viral load testing for those with elevated viral loads: a national perspective from South Africa. J. Int. AIDS Soc. 2020;23:e25542.
11.
go back to reference Eisinger RW, Dieffenbach CW, Fauci AS. HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. JAMA. 2019;321:451.CrossRef Eisinger RW, Dieffenbach CW, Fauci AS. HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. JAMA. 2019;321:451.CrossRef
12.
go back to reference Beyrer, C. Consolidated Guidelines on Hiv Prevention, Diagnosis, Treatment and Care for Key Populations. (World Health Organization, 2016). Beyrer, C. Consolidated Guidelines on Hiv Prevention, Diagnosis, Treatment and Care for Key Populations. (World Health Organization, 2016).
13.
go back to reference Nakalega R, et al. Linkage to intensive adherence counselling among HIV-positive persons on ART with detectable viral load in Gomba district, rural Uganda. AIDS Res. Ther. 2021;18:15. Nakalega R, et al. Linkage to intensive adherence counselling among HIV-positive persons on ART with detectable viral load in Gomba district, rural Uganda. AIDS Res. Ther. 2021;18:15.
14.
go back to reference WHO, W. H. O. HIV Treatment and Care: WHO HIV Policy Adoption and Implementation Status in Countries. (2018). WHO, W. H. O. HIV Treatment and Care: WHO HIV Policy Adoption and Implementation Status in Countries. (2018).
15.
go back to reference Rangarajan S, et al. Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. J. Virus Erad. 2016;2:94–101. Rangarajan S, et al. Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. J. Virus Erad. 2016;2:94–101.
16.
go back to reference Engsig FN, et al. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clin. Infect. Dis. 2014;58:1312–21. Engsig FN, et al. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clin. Infect. Dis. 2014;58:1312–21.
17.
go back to reference Cohen MS, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N. Engl. J. Med. 2011;365:493–505. Cohen MS, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N. Engl. J. Med. 2011;365:493–505.
18.
go back to reference Fatti G, Shaikh N, Eley B, Grimwood A. Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: A multicentre cohort study from South Africa. AIDS Care. 2014;26:448–53.CrossRef Fatti G, Shaikh N, Eley B, Grimwood A. Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: A multicentre cohort study from South Africa. AIDS Care. 2014;26:448–53.CrossRef
19.
go back to reference Fatti G, Mothibi E, Meintjes G, Grimwood A. Antiretroviral Treatment Outcomes amongst Older Adults in a Large Multicentre Cohort in South Africa. PLoS ONE. 2014;9:e100273.CrossRef Fatti G, Mothibi E, Meintjes G, Grimwood A. Antiretroviral Treatment Outcomes amongst Older Adults in a Large Multicentre Cohort in South Africa. PLoS ONE. 2014;9:e100273.CrossRef
20.
go back to reference Ministry of Health. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. (2018). Ministry of Health. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. (2018).
21.
go back to reference UBOS and ICF, U. B. of S. Uganda Demographic and Health Survey 2016. (2018). UBOS and ICF, U. B. of S. Uganda Demographic and Health Survey 2016. (2018).
22.
go back to reference Vlahov D, et al. Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4 + Cell Count. JAMA. 1998;279:35.CrossRef Vlahov D, et al. Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4 + Cell Count. JAMA. 1998;279:35.CrossRef
23.
go back to reference Wiley CA, et al. Distribution of Brain HIV Load in AIDS. Brain Pathol. 2006;8:277–84.CrossRef Wiley CA, et al. Distribution of Brain HIV Load in AIDS. Brain Pathol. 2006;8:277–84.CrossRef
24.
go back to reference Van Dyke RB, et al. Reported Adherence as a Determinant of Response to Highly Active Antiretroviral Therapy in Children Who Have Human Immunodeficiency Virus Infection. PEDIATRICS. 2002;109:e61–1. Van Dyke RB, et al. Reported Adherence as a Determinant of Response to Highly Active Antiretroviral Therapy in Children Who Have Human Immunodeficiency Virus Infection. PEDIATRICS. 2002;109:e61–1.
25.
go back to reference Murphy RA, et al. Outcomes After Virologic Failure of First-line ART in South Africa. AIDS Lond. Engl. 2010;24:1007–12. Murphy RA, et al. Outcomes After Virologic Failure of First-line ART in South Africa. AIDS Lond. Engl. 2010;24:1007–12.
26.
go back to reference Kim MJ, et al. Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching. Infect. Chemother. 2015;47:231. Kim MJ, et al. Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching. Infect. Chemother. 2015;47:231.
27.
go back to reference Reynolds SJ, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS Lond. Engl. 2009;23:697–700. Reynolds SJ, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS Lond. Engl. 2009;23:697–700.
28.
go back to reference Bonner K, et al. Expanding Access to HIV Viral Load Testing: A Systematic Review of RNA Stability in EDTA Tubes and PPT beyond Current Time and Temperature Thresholds. PLoS ONE. 2014;9:e113813.CrossRef Bonner K, et al. Expanding Access to HIV Viral Load Testing: A Systematic Review of RNA Stability in EDTA Tubes and PPT beyond Current Time and Temperature Thresholds. PLoS ONE. 2014;9:e113813.CrossRef
29.
go back to reference Nasuuna E, et al. Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda. BMC Public Health. 2018;18:1048.CrossRef Nasuuna E, et al. Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda. BMC Public Health. 2018;18:1048.CrossRef
30.
go back to reference Fox MP, et al. Delays in repeat HIV viral load testing for those with elevated viral loads: a national perspective from South Africa. J. Int. AIDS Soc. 2020;23:e25542.CrossRef Fox MP, et al. Delays in repeat HIV viral load testing for those with elevated viral loads: a national perspective from South Africa. J. Int. AIDS Soc. 2020;23:e25542.CrossRef
31.
go back to reference Phillips AN. HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load. JAMA. 2001;286:2560.CrossRef Phillips AN. HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load. JAMA. 2001;286:2560.CrossRef
32.
go back to reference Havlir DV, et al. Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing Regimens. JAMA. 2000;283:229–34.CrossRef Havlir DV, et al. Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing Regimens. JAMA. 2000;283:229–34.CrossRef
33.
go back to reference Fung SK, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. 2005;43:937–43.CrossRef Fung SK, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. 2005;43:937–43.CrossRef
34.
go back to reference Pannus P, et al. Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription. J. Int. AIDS Soc. 2020;23. Pannus P, et al. Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription. J. Int. AIDS Soc. 2020;23.
36.
go back to reference De Scheerder M-A, et al. HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs. Cell Host Microbe. 2019;26:347–358.e7.CrossRef De Scheerder M-A, et al. HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs. Cell Host Microbe. 2019;26:347–358.e7.CrossRef
37.
go back to reference Howard AA, El-Sadr WM. Integration of Tuberculosis and HIV Services in Sub-Saharan Africa: Lessons Learned. Clin. Infect. Dis. 2010;50:S238–44.CrossRef Howard AA, El-Sadr WM. Integration of Tuberculosis and HIV Services in Sub-Saharan Africa: Lessons Learned. Clin. Infect. Dis. 2010;50:S238–44.CrossRef
38.
go back to reference Jimmy B, Jose J. Patient Medication Adherence: Measures in Daily Practice. Oman Med. J. 2011;26:155.CrossRef Jimmy B, Jose J. Patient Medication Adherence: Measures in Daily Practice. Oman Med. J. 2011;26:155.CrossRef
39.
go back to reference Group, B. M. J. P. Declaration of Helsinki (1964). BMJ 313, 1448–1449 (1996). Group, B. M. J. P. Declaration of Helsinki (1964). BMJ 313, 1448–1449 (1996).
40.
go back to reference von Elm E, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Int. J. Surg. 2014;12:1495–9.CrossRef von Elm E, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Int. J. Surg. 2014;12:1495–9.CrossRef
41.
go back to reference Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90 An ambitious treatment target to help end the AIDS epidemic. (2014). Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90 An ambitious treatment target to help end the AIDS epidemic. (2014).
45.
go back to reference Tanner Z, et al. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infect. Dis. 2016;16. Tanner Z, et al. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infect. Dis. 2016;16.
46.
go back to reference Chendi BH, et al. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study. BMC Infect. Dis. 2019;19:194.CrossRef Chendi BH, et al. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study. BMC Infect. Dis. 2019;19:194.CrossRef
47.
go back to reference Bulage L, et al. Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015. BMC Infect. Dis. 2017;17:326.CrossRef Bulage L, et al. Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015. BMC Infect. Dis. 2017;17:326.CrossRef
Metadata
Title
Unsuppressed viral load after intensive adherence counselling in rural eastern Uganda; a case of Kamuli district, Uganda
Authors
Geoffrey Ndikabona
John Bosco Alege
Nicholas Sebuliba Kirirabwa
Derrick Kimuli
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2021
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-021-12366-4

Other articles of this Issue 1/2021

BMC Public Health 1/2021 Go to the issue